✦ LIBER ✦

35 Efficacy of preemptive treatment strategy for Cytomegalovirus (CMV) high-risk (D+/R-) renal transplant recipients

✍ Scribed by M. Ruesch; M. Weber; J.D. Seebach; R.P. Wüthrich; N.J. Mueller

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical Utility of Cytomegalovirus (CMV

✍ Atul Humar; Tony Mazzulli; George Moussa; Raymund R. Razonable; Carlos V. Paya; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB

Prophylactic Versus Preemptive Oral Valg

✍ J. A. Khoury; G. A. Storch; D. L. Bohl; R. M. Schuessler; S. M. Torrence; M. Loc 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 323 KB

Efficacy and Safety of Valgancyclovir as

✍ C. Dı́az-Pedroche; C. Lumbreras; P. Del Valle; R. San Juan; S. Hernando; D. Folg 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 51 KB

PIN83 Cost-Effectiveness and Cost-Utilit

✍ P. Kawalec; P. Holko; M. Boratynska; M. Glyda; E. Ignacak; M. Russel-Szymczyk; M 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

Prophylactic and preemptive strategies f

📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 174 KB

Rejection treatment and CMV infection as

📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 110 KB